Key result
Achieving BP, glucose, and LDL-C targets is linked to ~35% lower cardiovascular-renal risk.
Why the study?
Does achieving multiple metabolic targets reduce cardiovascular-renal events and mortality across different stages of cardiovascular-kidney-metabolic syndrome?
Observational
Yes
Does achieving multiple metabolic targets reduce cardiovascular-renal events and mortality across different stages of cardiovascular-kidney-metabolic syndrome?
Effect estimate: HR 0.65 (95% CI 0.57-0.73)
Achieving comprehensive metabolic control (BP, glucose, LDL-C) significantly reduces cardiorenal events and mortality in early stages of cardiovascular-kidney-metabolic syndrome, but this benefit attenuates in advanced stages.
Supports metabolic targets in early CKM stages; hypothesis-generating for advanced stages, requires prospective confirmation.
BACKGROUND The extent to which achieving multiple metabolic treatment targets confers sustained cardiorenal protection across all stages of cardiovascular - kidney - metabolic (CKM) syndrome remains uncertain. METHODS This multicenter retrospective study used data from the China Renal Data System (CRDS) to investigate the association between achieving multiple metabolic targets (blood pressure, fasting blood glucose, LDL-C control) and cardiorenal outcomes across stages of CKM syndrome. RESULTS The proportion of patients meeting all three metabolic targets decreased markedly with advancing CKM stage. Kaplan-Meier curves showed increasing risks of cardiovascular-renal events and mortality across higher stages (P < 0.001). After adjustment, higher metabolic scores were linked to lower risks: for cardiovascular-renal outcomes, HR 0.82 (95% CI 0.77-0.87) for score 1, 0.72 (0.68-0.77) for score 2, and 0.65 (0.57-0.73) for score 3. Stratified analysis showed significant risk reduction in early CKM stages but not in advanced stages. Restricted cubic spline models indicated nonlinear associations between LDL-C and both outcomes, and between FBG, systolic BP, and mortality, after full adjustment (all P < 0.05). CONCLUSIONS The findings underscore the need for stage-specific management strategies in CKM syndrome.
No takes yet. Share an insight, caveat, or question.
Cai et al. (2026) conducted an observational in Cardiovascular-kidney-metabolic (CKM) syndrome. Achieving multiple metabolic targets (blood pressure, fasting blood glucose, LDL-C control) vs. Lower metabolic target achievement was evaluated on Cardiovascular-renal outcomes (HR 0.65, 95% CI 0.57-0.73). Achieving three metabolic targets (blood pressure, fasting blood glucose, LDL-C) was associated with a lower risk of cardiovascular-renal outcomes (HR 0.65; 95% CI 0.57-0.73).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: